<DOC>
	<DOCNO>NCT01405586</DOCNO>
	<brief_summary>The purpose study evaluate addition cisplatin first-line chemotherapy gemcitabine elderly patient non small cell lung cancer term overall survival .</brief_summary>
	<brief_title>MILES-3 : Cisplatin Combination With Gemcitabine Elderly Patients With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Cytological histological diagnosis non smallcell lung cancer ( NSCLC ) Stage III B Stage IV disease Age &gt; = 70 year ECOG Performance status 0 1 Patient first diagnosis recurrence primary surgery At least one target nontarget lesion accord RECIST criterion Life expectancy least 3 month Neutrophils &gt; 1500/mm3 , platelet &gt; 100,000/mm3 , hemoglobin &gt; 10g/dl Creatinine &lt; 1.5 x upper normal limit AST ALT &lt; 2.5 x upper normal limit ( &lt; 5 x upper normal limit presence hepatic metastasis ) Bilirubin &lt; 1.5 x upper normal limit Signed informed consent Previous chemotherapy advance disease History malignant neoplasm within previous 5 year ( include nonmelanoma skin carcinoma insitu carcinoma uterine cervix , provide adequately treat ) Symptomatic cerebral spinal cord metastasis Myocardial infarct within last 12 month Systemic disease control treatment ( active infection , cardiovascular , hepatic , renal metabolic ) would , opinion investigator , permit patient undergo chemotherapy . Known suspected hypersensitivity drug use study Medical psychological condition opinion investigator would permit patient complete study give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>elderly</keyword>
	<keyword>chemotherapy</keyword>
</DOC>